Skip to main content

Community-Acquired Pneumonia Management Based on the PIRO System. A New Therapeutic Paradigm

  • Chapter
Management of Sepsis: The PIRO Approach

In 2001, an International Sepsis Defi nition Conference [1] agreed to assess the strengths and weaknesses of the criteria for sepsis established in 1991 [2], and, if necessary, to update them. The update was necessary because the current understanding of host response was very simplistic, and the concepts of sepsis, severe sepsis, and septic shock were very robust for daily clinical practice. Moreover, the signs and symptoms of sepsis are more varied than the initial criteria. A staging system had to be developed that would characterize the progression of sepsis. A new system was proposed based on four features — predisposition, infection, response, and organ dysfunction — the PIRO system [3–6].

This new conceptual framework for understanding sepsis, called the PIRO concept, is a classifi cation scheme that can stratify patients based on their predisposing conditions, the nature and extend of the insult, the nature and magnitude of the host response, and the degree of the concomitant organ dysfunction. Conceptually, it was modeled on the TNM classifi cation, which has been successfully used to defi ne prognostic indicators in clinical oncology. PIRO was introduced as a hypothesis-generating model for future research, but its practical applications were limited. In this chapter we propose a new paradigm for the management of CAP based on the PIRO system (Table 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Levy MM, Fink MP, Marshall JC, et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Defi nitions Conference. Crit Care Med 31(4):1250–1256

    Article  PubMed  Google Scholar 

  2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RA, Sibbald WJ (1992) Defi nitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644–1655

    Article  PubMed  CAS  Google Scholar 

  3. Angus DC, Burgner D, Wunderink R, et al. (2003) The PIRO concept: P is for predisposition. Crit Care 7:248–251

    Article  PubMed  Google Scholar 

  4. Vincent JL, Opal S, Torres A, et al. (2003) The PIRO concept: I is for infection. Crit Care 7:252–255

    Article  PubMed  Google Scholar 

  5. Gerlach H, Dhainaut JF, Harbarth S, et al. (2003) The PIRO concept: R is for response. Crit Care 7:256–259

    Article  PubMed  Google Scholar 

  6. Vincent JL, Wendon J, Groeneveld J, et al. (2003) The PIRO concept: O is for organ dysfunction. Crit Care 7:260–264

    Article  PubMed  Google Scholar 

  7. Nichol K, Nordin J, Nelson D, et al. (2007) Effectiveness of infl uenza vaccine in the community-dwelling elderly. N Engl J Med 357:1373–1381

    Article  PubMed  CAS  Google Scholar 

  8. Fine MJ, Smith MA, Carson CA, et al. (1994) Effi cacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Int Med 154:2666–2677

    CAS  Google Scholar 

  9. Woo J, Ho SC, Mak YT, et al. (1994) Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial. Age Ageing 23:40–48

    Article  PubMed  CAS  Google Scholar 

  10. Centers for Disease Control and Prevention (2001) Prevention and control of infl uenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 50(RR-04):1–46

    Google Scholar 

  11. Branger J, Florquin S, Knapp S, Leemans JC, Pater JM, Speelman P, Golenbock DT, Van der Poll T (2004) Role of toll-like receptor 4 in Gram-positive and Gram-negative pneumonia in mice. Infect Immun 72:788–794

    Article  PubMed  CAS  Google Scholar 

  12. Waterer GW, Wunderink RG (2005) Genetic susceptibility to pneumonia. Clin Chest Med 26:29–38

    Article  PubMed  Google Scholar 

  13. Almirall J, Gonzalez C, Balanzo X, Bolivar I (1999). Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 116:692–697

    Article  Google Scholar 

  14. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, et al. (2000) Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342:681–689

    Article  PubMed  CAS  Google Scholar 

  15. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, de la Torre M V, Sirvent JM, Bodi M (2006) Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 27:1210–1216

    Article  PubMed  CAS  Google Scholar 

  16. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E (2008). Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300:2407–2416

    Article  PubMed  CAS  Google Scholar 

  17. Menéndez R, Torres A, Zalacaín R, et al. (2004). Risk factors of treatment failure in community-acquired pneumonia: implications for disease outcome. Thorax 59:960–965

    Article  PubMed  Google Scholar 

  18. Ortqvist A, Hedlund J, Kalin M (2005) Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 26(6):563–574

    Article  PubMed  Google Scholar 

  19. Rello J, Bodi M, Mariscal D, Navarro M, Díaz E, Gallego M, Valles J (2003) Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest Jan 123(1):174–180

    Article  Google Scholar 

  20. Bodi M, Rodriguez A, Sole-Violan J, Gilavert MC, Garnacho J, Blanquer J, Jimenez J, de la Torre M V, Sirvent JM, Almirall J, et al. (2005): Antibiotic prescribing for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America Guidelines on survival. Clin Infect Dis 41:1709–1716

    Article  PubMed  CAS  Google Scholar 

  21. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080–2084

    Article  PubMed  CAS  Google Scholar 

  22. Kahn LK, Rogers WH, Rubenstein LV, et al. (1990) Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system. JAMA 264:1969–1973

    Article  PubMed  CAS  Google Scholar 

  23. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG (2004) Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Int Med 164:637–644. Abstract

    Article  Google Scholar 

  24. Waterer GW, Kessler LA, Wunderink RG (2006) Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 130:11–15

    Article  PubMed  Google Scholar 

  25. Hirata N, Hiramatsu K, Kishi K, Yamasaki T, Ichimiya T, Nasu M (2001) Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of infl am-matory cytokines. Antimicrob Agents Chemother 45:2638–2642

    Article  PubMed  CAS  Google Scholar 

  26. Tilghman C, Finland M (1937) Clinical signifi cance of bacteremia in pneumococci pneumonia. Arch Int Med 59:602–619

    Google Scholar 

  27. Austrian R, Gold J (1964) Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Int Med 60:759–776

    PubMed  CAS  Google Scholar 

  28. Bordon J, Peyrani P, Brock GN, Blasi F, Rello J, File T, Ramirez J (2008) The presence of pneumococcal bacteremia does not infl uence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest 133:618–624

    Article  PubMed  Google Scholar 

  29. Waterer GW, Somes GW, Wunderick RG (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842

    Article  PubMed  CAS  Google Scholar 

  30. Mart'nez JA, Horcajada JP, Almeda M, et al. (2003) Addition of a macrolide to a b-lactam- based empirical antibiotic regimen is associated with lower in-hospital morality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389–395

    Article  Google Scholar 

  31. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, et al. (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:440–444

    Article  PubMed  Google Scholar 

  32. Yamasawa H, Osikawa O, Ohno S, Sugiyama Y (2004) Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol 30:569–575

    Article  PubMed  CAS  Google Scholar 

  33. Reato G, Cuffi ni AM, Tullio V, et al. (2004) Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. Int J Antimicrob Agents 23: 150–154

    Article  PubMed  CAS  Google Scholar 

  34. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al. (2004) Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 48:93–99

    Article  CAS  Google Scholar 

  35. De Hennezel L, Ramisse F, Binder P, et al. (2001) Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model. Antimicrob Agents Chemother 45:316–318

    Article  PubMed  Google Scholar 

  36. Chiou CC, Yu LV (2006) Severe pneumococcal pneumonia: new strategies for management. Curr Opin Crit Care 12:470–476

    PubMed  Google Scholar 

  37. Morgan MS (2007) Diagnosis and treatment of Panton-Valentine leukocidin (PVL)-associated staphylococcal pneumonia. Int J Antimicrob Agents 30:289–296

    Article  PubMed  CAS  Google Scholar 

  38. Casadevall A, Scharff M (1995) Return to the past: the case for antibody-based therapy in infectious diseases. Clin Infect Dis 21:150–161

    PubMed  CAS  Google Scholar 

  39. Lisboa T, Blot S, Waterer GW, Canalis E, de Mendoza D, Rodriguez A, Rello J (2009) Radiological progression of pulmonary infi ltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest 135:165–172

    Article  PubMed  Google Scholar 

  40. Lim TK (2001) Management of parapneumonic pleural effusion. Curr Opin Pulm Med Jul 7(4):193–197

    Article  CAS  Google Scholar 

  41. Colice GL, Curtis A, Deslauriers J, et al. (2000) Medical and surgical treatment of parapneu-monic effusions: an evidence-based guideline. Chest 118(4):1158–1171

    Article  PubMed  CAS  Google Scholar 

  42. Blot SI, Rodriguez A, Solé-Violán J, Blanquer J, Almirall J, Rello J (2007) Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 35:2509–2514

    Article  PubMed  Google Scholar 

  43. Stephens DP, Fisher DA, Currie BJ (2002) An audit of the use of granulocyte colony-stimulating factor in septic shock. Int Med J 32:143–148

    Article  CAS  Google Scholar 

  44. Hartung T (1999) Granulocyte colony-stimulating factor; its potential role in infectious disease. Acquir Immune Defi c Syndr; 13 Suppl 2:3–9

    Google Scholar 

  45. Cheng AC, Stephens DP, Currie BJ (2007) Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev; CD004400

    Google Scholar 

  46. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) I ntensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367

    Article  PubMed  Google Scholar 

  47. Krinsley JS (2004) Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79:992–1000

    Article  PubMed  Google Scholar 

  48. Preiser JC (2007) Intensive glycemic control in med-surg patients (European Glucontrol trial). Program and abstracts of the Society of Critical Care Medicine 36th Critical Care Congress, February 17–21, Orlando, Florida

    Google Scholar 

  49. Becker T, Moldoveanu A, Cukierman T, et al. (2007) Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diab Res Clin Pract 78:392–397

    Article  Google Scholar 

  50. Cooper MS, Stewart PM (2003) Corticosteroid Insuffi ciency in Acutely Ill Patients N Engl J Med 348:727–734

    Article  PubMed  CAS  Google Scholar 

  51. Monton C, Ewig S, Torres A, et al. (1999) Role of glucocorticoids on infl ammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 14:218–220

    Article  PubMed  CAS  Google Scholar 

  52. Barnes PJ (2006) Corticosteroid effects on cell signaling. Eur Respir J 27:413–426

    Article  PubMed  CAS  Google Scholar 

  53. Mikami K, Suzuki M, Kitagawa H, et al. (2007) Effi cacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 185:249–255

    Article  PubMed  CAS  Google Scholar 

  54. Confalonieri M, Urbino R, Potena A, et al. (2005) Hydrocortisone infusion in patients with severe community-acquired pneumonia: results of a randomized clinical trial. Am J Respir Crit Care Med 171:242–248

    Article  PubMed  Google Scholar 

  55. Marik P, Kraus P, Sribante J, et al. (1993) Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest 104:389–392

    Article  PubMed  CAS  Google Scholar 

  56. Wagner HN, Bennet IL, Lasagna L, et al. (1995) The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 98:197–215

    Google Scholar 

  57. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J, CORTICUS (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124

    Article  PubMed  CAS  Google Scholar 

  58. Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados M V, Sole-Violan J, Rello J (2007) Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med Jun 35:1493–1498

    Article  CAS  Google Scholar 

  59. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A (2009) Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Eur Respir J 33(1):153–159

    Article  PubMed  CAS  Google Scholar 

  60. Parnham MJ (2005) Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18:125–131

    Article  PubMed  CAS  Google Scholar 

  61. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952–961

    Article  PubMed  Google Scholar 

  62. Rivers E, Nguyen B, Havstad S, et al. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377

    Article  PubMed  CAS  Google Scholar 

  63. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, Tomlanovich MC (2004) Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 32:1637–1642

    Article  PubMed  Google Scholar 

  64. Confalonieri M, Potena A, Carbone G, et al. (1999) Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 160:1585–1591

    PubMed  CAS  Google Scholar 

  65. Dreyfuss D, Saumon G (1998) Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med 157:294–323

    PubMed  CAS  Google Scholar 

  66. Slutsky AS, Tremblay LN (1998) Multiple system organ failure. Is mechanical ventilation a contributing factor? Am J Respir Crit Care Med 157:1721–1725

    PubMed  CAS  Google Scholar 

  67. The Acute Respiratory Distress Syndrome Network. (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301–1308

    Article  Google Scholar 

  68. Rogiers P, Zhang H, Smail N, et al. (1999) Continuous venovenous hemofi ltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 27:1848–1855

    Article  PubMed  CAS  Google Scholar 

  69. Ronco C, Bellomo R, Homel P, et al. (2000) Effects of different doses in continuous veno-venous haemofi ltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26–30

    Article  PubMed  CAS  Google Scholar 

  70. Jakob SM, Frey FJ, Uehlinger DE (1996) Does continuous renal replacement therapy favourably infl uence the outcome of the patients? Nephrol Dial Transplant 11:1250–1255

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Martin-Loeches, I., Rello, J. (2009). Community-Acquired Pneumonia Management Based on the PIRO System. A New Therapeutic Paradigm. In: Rello, J., Díaz, E., Rodríguez, A. (eds) Management of Sepsis: The PIRO Approach. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00479-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-00479-7_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-00478-0

  • Online ISBN: 978-3-642-00479-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics